Head-To-Head Comparison: Gain Therapeutics (NASDAQ:GANX) & NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Valuation and Earnings

This table compares NRx Pharmaceuticals and Gain Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	N/A	N/A	-$25.13 million	($2.35)	-0.89
Gain Therapeutics	$50,000.00	1,938.38	-$20.41 million	($0.61)	-4.13

Gain Therapeutics has higher revenue and earnings than NRx Pharmaceuticals. Gain Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

NRx Pharmaceuticals has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for NRx Pharmaceuticals and Gain Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1	1	4	0	2.50
Gain Therapeutics	1	0	5	0	2.67

NRx Pharmaceuticals currently has a consensus target price of $38.00, suggesting a potential upside of 1,726.92%. Gain Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 217.46%. Given NRx Pharmaceuticals’ higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Gain Therapeutics.

Insider and Institutional Ownership

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by insiders. Comparatively, 7.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares NRx Pharmaceuticals and Gain Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-395.06%
Gain Therapeutics	N/A	-341.32%	-174.09%

Summary

Gain Therapeutics beats NRx Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

About Gain Therapeutics

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.